BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 32413460)

  • 1. Optimizing neuromelanin contrast in the substantia nigra and locus coeruleus using a magnetization transfer contrast prepared 3D gradient recalled echo sequence.
    Liu Y; Li J; He N; Chen Y; Jin Z; Yan F; Haacke EM
    Neuroimage; 2020 Sep; 218():116935. PubMed ID: 32413460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach.
    Chen X; Huddleston DE; Langley J; Ahn S; Barnum CJ; Factor SA; Levey AI; Hu X
    Magn Reson Imaging; 2014 Dec; 32(10):1301-6. PubMed ID: 25086330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: Combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson's disease.
    He N; Ghassaban K; Huang P; Jokar M; Wang Y; Cheng Z; Jin Z; Li Y; Sethi SK; He Y; Chen Y; Gharabaghi S; Chen S; Yan F; Haacke EM
    Neuroimage; 2021 Apr; 230():117810. PubMed ID: 33524572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes.
    Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L
    Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients.
    Reimão S; Pita Lobo P; Neutel D; Correia Guedes L; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    Eur J Neurol; 2015 Mar; 22(3):540-6. PubMed ID: 25534480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromelanin related ultra-high field signal intensity of the locus coeruleus differs between Parkinson's disease and controls.
    Wolters AF; Heijmans M; Priovoulos N; Jacobs HIL; Postma AA; Temel Y; Kuijf ML; Michielse S
    Neuroimage Clin; 2023; 39():103479. PubMed ID: 37494758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuromelanin in parkinsonian disorders: an update.
    Martin-Bastida A; Pietracupa S; Piccini P
    Int J Neurosci; 2017 Dec; 127(12):1116-1123. PubMed ID: 28460588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An investigation of neuromelanin distribution in substantia nigra and locus coeruleus in patients with Parkinson's disease using neuromelanin-sensitive MRI.
    Liu Q; Wang P; Liu C; Xue F; Wang Q; Chen Y; Hou R; Chen T
    BMC Neurol; 2023 Aug; 23(1):301. PubMed ID: 37580712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative magnetization transfer imaging of the human locus coeruleus.
    Trujillo P; Petersen KJ; Cronin MJ; Lin YC; Kang H; Donahue MJ; Smith SA; Claassen DO
    Neuroimage; 2019 Oct; 200():191-198. PubMed ID: 31233908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo detection of substantia nigra and locus coeruleus volume loss in Parkinson's disease using neuromelanin-sensitive MRI: Replication in two cohorts.
    Hwang KS; Langley J; Tripathi R; Hu XP; Huddleston DE
    PLoS One; 2023; 18(4):e0282684. PubMed ID: 37053195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Automatic detection of neuromelanin and iron in the midbrain nuclei using a magnetic resonance imaging-based brain template.
    Jin Z; Wang Y; Jokar M; Li Y; Cheng Z; Liu Y; Tang R; Shi X; Zhang Y; Min J; Liu F; He N; Yan F; Haacke EM
    Hum Brain Mapp; 2022 Apr; 43(6):2011-2025. PubMed ID: 35072301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reproducibility of locus coeruleus and substantia nigra imaging with neuromelanin sensitive MRI.
    Langley J; Huddleston DE; Liu CJ; Hu X
    MAGMA; 2017 Apr; 30(2):121-125. PubMed ID: 27687624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling the contributions to the neuromelanin-MRI contrast.
    Priovoulos N; van Boxel SCJ; Jacobs HIL; Poser BA; Uludag K; Verhey FRJ; Ivanov D
    Brain Struct Funct; 2020 Dec; 225(9):2757-2774. PubMed ID: 33090274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locus coeruleus and substantia nigra neuromelanin magnetic resonance imaging differentiates Parkinson's disease and essential tremor.
    Wang X; Huang P; Haacke EM; Liu Y; Zhang Y; Jin Z; Li Y; Xu Q; Liu P; Chen S; He N; Yan F
    Neuroimage Clin; 2023; 38():103420. PubMed ID: 37141646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visualization of neuromelanin in the Substantia nigra and locus ceruleus at 1.5T using a 3D-gradient echo sequence with magnetization transfer contrast.
    Nakane T; Nihashi T; Kawai H; Naganawa S
    Magn Reson Med Sci; 2008; 7(4):205-10. PubMed ID: 19110515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosing Parkinson's disease by combining neuromelanin and iron imaging features using an automated midbrain template approach.
    Jokar M; Jin Z; Huang P; Wang Y; Zhang Y; Li Y; Cheng Z; Liu Y; Tang R; Shi X; Min J; Liu F; Chen S; He N; Haacke EM; Yan F
    Neuroimage; 2023 Feb; 266():119814. PubMed ID: 36528314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normative Values of Neuromelanin-Sensitive MRI Signal in Older Adults Obtained Using a Turbo Spin Echo Sequence.
    Al Haddad R; Chamoun M; Tardif CL; Guimond S; Horga G; Rosa-Neto P; Cassidy CM
    J Magn Reson Imaging; 2023 Jul; 58(1):294-300. PubMed ID: 36373996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Locus Coeruleus and Substantia Nigra Pathology With Cognitive and Motor Functions in Patients With Parkinson Disease.
    Prasuhn J; Prasuhn M; Fellbrich A; Strautz R; Lemmer F; Dreischmeier S; Kasten M; Münte TF; Hanssen H; Heldmann M; Brüggemann N
    Neurology; 2021 Sep; 97(10):e1007-e1016. PubMed ID: 34187859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy.
    Simões RM; Castro Caldas A; Grilo J; Correia D; Guerreiro C; Pita Lobo P; Valadas A; Fabbri M; Correia Guedes L; Coelho M; Rosa MM; Ferreira JJ; Reimão S
    BMC Neurol; 2020 Nov; 20(1):432. PubMed ID: 33243166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
    Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
    J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.